Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) Director Alan Bruce Montgomery sold 2,215 shares of the firm’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $20,422.30. Following the completion of the transaction, the director now owns 20,611 shares of the company’s stock, valued at $190,033.42. This trade represents a 9.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xencor Price Performance

NASDAQ:XNCR opened at $9.05 on Tuesday. Xencor, Inc. has a 52 week low of $7.16 and a 52 week high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $644.10 million, a PE ratio of -2.83 and a beta of 0.87. The stock’s 50-day moving average price is $9.08 and its 200-day moving average price is $14.92.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The company had revenue of $32.73 million during the quarter, compared to analysts’ expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company’s quarterly revenue was up 104.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.11) earnings per share. As a group, equities analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Primecap Management Co. CA lifted its stake in Xencor by 8.6% in the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock valued at $103,857,000 after buying an additional 776,580 shares in the last quarter. Vanguard Group Inc. lifted its stake in Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after purchasing an additional 418,040 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Xencor by 2.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company’s stock worth $92,758,000 after purchasing an additional 107,350 shares in the last quarter. BVF Inc. IL lifted its stake in Xencor by 19.7% in the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company’s stock worth $29,155,000 after purchasing an additional 451,381 shares in the last quarter. Finally, TCG Crossover Management LLC lifted its stake in Xencor by 1.0% in the 4th quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company’s stock worth $56,350,000 after purchasing an additional 25,000 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on XNCR. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Xencor in a research report on Wednesday, April 30th. William Blair began coverage on Xencor in a research report on Monday, April 21st. They set an “outperform” rating on the stock. Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, Barclays dropped their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.